Skip to main content
OpenTrials

Clinical trial condition

Multiple Myeloma

Explore clinical trials studying Multiple Myeloma. Study availability and eligibility vary by location and protocol.

1,662 public trials 323 recruiting studies
Refine in advanced search Browse all conditions

Multiple Myeloma trial results

Completed

Short Course Daratumumab in Patients With Multiple Myeloma

NCT03490344

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Memoral Sloan Kettering Basking Ridge Basking Ridge, New Jersey, United States
  • Memoral Sloan Kettering Monmouth Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen Montvale, New Jersey, United States
  • Memorial Sloan Kettering Commack Commack, New York, United States
View Trial Details
Completed

Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial

NCT03941860

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Cancer Center at Saint Joseph's Phoenix, Arizona, United States
  • CHI Saint Vincent Cancer Center Hot Springs Hot Springs, Arkansas, United States
  • Mission Hope Medical Oncology - Arroyo Grande Arroyo Grande, California, United States
  • Pacific Central Coast Health Center-San Luis Obispo San Luis Obispo, California, United States
View all 222 locations
View Trial Details
Completed

A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

NCT02519452

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Atlanta, Georgia, United States
  • New York, United States
  • Charlotte, North Carolina, United States
  • Philadelphia, Pennsylvania, United States
View Trial Details
Completed

Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma

NCT03361748

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • Local Institution - 108 San Francisco, California, United States
  • University of California - San Francisco San Francisco, California, United States
  • Emory University Atlanta, Georgia, United States
  • Local Institution - 103 Atlanta, Georgia, United States
View all 48 locations
View Trial Details
Completed

A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

NCT02076009

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Little Rock, Arkansas, United States
  • Gainesville, Florida, United States
  • West Palm Beach, Florida, United States
  • Atlanta, Georgia, United States
View all 145 locations
View Trial Details
Completed

A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma

NCT03277105

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Levine Cancer Institute Charlotte, North Carolina, United States
  • Royal Prince Alfred Hospital Camperdown, Australia
  • St Vincents Hospital Melbourne Fitzroy, Australia
View all 146 locations
View Trial Details
Completed

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

NCT03412565

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Cancer Center of Central Connecticut - Southington Southington, Connecticut, United States
  • Mayo Clinic in Florida Jacksonville, Florida, United States
  • UF Health Cancer Center at Orlando Health Orlando, Florida, United States
  • Karmonos Cancer Institute Detroit, Michigan, United States
View all 64 locations
View Trial Details
Completed

A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma

NCT05347485

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • City of Hope Duarte, California, United States
  • University of California San Francisco San Francisco, California, United States
  • Stanford University Medical Center Stanford, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
View all 18 locations
View Trial Details

Related conditions